Health Care · NYSE: CAH
Cardinal Health earnings: results, call transcripts & KPI history
2 quarters · fiscal year ends June · next results expected around 4 Feb 2027
Latest: Q1 FY2027
Cardinal Health raised its fiscal 2027 outlook as brand and specialty pharma demand grew, a CVS Health distribution renewal was signed and a diabetes supplies acquisition was lined up.
Cardinal's pharmaceutical distribution business grew on brand and specialty drug sales from existing customers, helped by a better generics program. Its home-health, nuclear and logistics businesses (reported together as Other) grew across all three units. Medical products were flat: Cardinal Health Brand grew, but distribution and currency effects weighed. The company closed the Strive Medical acquisition, a multi-specialty supply provider focused on urology.
Read the Q1 FY2027 summary →Q1 FY2027 slides (PDF) ↗Official transcript (PDF) ↗
Quarters
KPI history
Fourth quarter worked out from the annual figure.
Data
| Q4 FY24 | $59.9B * |
| Q1 FY25 | $52.3B |
| Q2 FY25 | $55.3B |
| Q3 FY25 | $54.9B |
| Q4 FY25 | $60.2B * |
| Q1 FY26 | $64.0B |
| Q2 FY26 | $65.6B |
| Q1 FY27 | $67.5B |
Data
| Q1 FY25 | $1.70 |
| Q1 FY26 | $1.88 |
| Q1 FY27 | $2.38 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 FY24 | 0.7% |
| Q1 FY25 | 1.1% |
| Q2 FY25 | 1.0% |
| Q3 FY25 | 1.3% |
| Q4 FY25 | 0.7% |
| Q1 FY26 | 1.0% |
| Q2 FY26 | 1.1% |
| Q1 FY27 | 1.1% |
Data
| Q4 FY24 | $1.9B |
| Q1 FY25 | -$1.7B |
| Q2 FY25 | -$495.0M |
| Q3 FY25 | $2.8B |
| Q4 FY25 | $1.3B |
| Q1 FY26 | $865.0M |
| Q2 FY26 | $555.0M |
| Q1 FY27 | $1.2B |
Operating cash flow minus capital expenditure, from cash flow statements.
| Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q1 FY27 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $59.9Bd | $52.3B | $55.3B | $54.9B | $60.2Bd | $64.0B | $65.6B | $67.5B |
| Gross margin | 3.1% | 3.6% | 3.5% | 3.9% | 3.7% | 3.6% | 3.7% | 3.8% |
| Operating income | $401.0Md | $568.0M | $549.0M | $730.0M | $428.0Md | $668.0M | $707.0M | $753.0M |
| Operating margin | 0.7% | 1.1% | 1.0% | 1.3% | 0.7% | 1.0% | 1.1% | 1.1% |
| Net income | $235.0Md | $416.0M | $400.0M | $506.0M | $239.0Md | $450.0M | $467.0M | $554.0M |
| Diluted EPS | — | $1.70 | — | — | — | $1.88 | — | $2.38 |
| Operating cash flow | $2.1Bd | -$1.6B | -$396.0Md | $2.9Bd | $1.5Bd | $973.0M | $686.0Md | $1.4B |
| Capital expenditure | $193.0Md | $90.0M | $99.0Md | $126.0Md | $232.0Md | $108.0M | $131.0Md | $157.0M |
| Free cash flow | $1.9B | -$1.7B | -$495.0M | $2.8B | $1.3B | $865.0M | $555.0M | $1.2B |
From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.
10-K and 10-Q filings
- 5 Nov 202610-Q for the period ended 30 Sep 2026SEC ↗
- 11 Aug 202610-K for the period ended 30 Jun 2026SEC ↗
- 30 Apr 202610-Q for the period ended 31 Mar 2026SEC ↗
- 5 Feb 202610-Q for the period ended 31 Dec 2025SEC ↗
- 30 Oct 202510-Q for the period ended 30 Sep 2025SEC ↗
- 12 Aug 202510-K for the period ended 30 Jun 2025SEC ↗
- 1 May 202510-Q for the period ended 31 Mar 2025SEC ↗
- 30 Jan 202510-Q for the period ended 31 Dec 2024SEC ↗